# systemic sclerosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/systemic-sclerosis

> 3 upcoming FDA catalysts in systemic sclerosis: Chemomab Therapeutics Ltd. (CMMB) on June 2028 (primary completion); BMS-986353 (BMY) on Nov 2028 to Feb 2029 (topline data readout); BMS-986353 (BMY) on November 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2024 | [APPROACH (tibulizumab) trial start](https://sec-api.dev/pdufa/tibulizumab) | ZURA | systemic sclerosis | completed | "In December 2024, we initiated TibuSURE, a global Phase 2 clinical study evaluating tibulizumab in adults with early diffuse cutaneous systemic sclerosis ("dcSSc")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1855644/000110465925110793/zura-20250930x10q.htm)) |
| June 2028 | [Chemomab Therapeutics Ltd. primary completion](https://sec-api.dev/companies/cmmb/catalysts) | CMMB | Systemic Sclerosis | delayed | "NCT06210945 (Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis): Overall Status SUSPENDED; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor ChemomAb Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06210945)) |
| Nov 2028 to Feb 2029 | [BMS-986353 topline data readout](https://sec-api.dev/pdufa/bms-986353) | BMY | Systemic Sclerosis | scheduled | "NCT07335562 (A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-11-14 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07335562)) |
| November 2028 | [BMS-986353 primary completion](https://sec-api.dev/pdufa/bms-986353) | BMY | Systemic Sclerosis | scheduled | "NCT07335562 (A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-11-14 (ESTIMATED); Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07335562)) |

## Drugs

- [APPROACH (tibulizumab)](https://sec-api.dev/pdufa/tibulizumab) (ZURA)
- [BMS-986353](https://sec-api.dev/pdufa/bms-986353) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/systemic-sclerosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "systemic sclerosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/systemic-sclerosis

```bibtex
@misc{secapidev_indications_systemic_sclerosis_20261116,
  title        = {systemic sclerosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/systemic-sclerosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_systemic_sclerosis_20261116","title":"systemic sclerosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/systemic-sclerosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
